Chronic Lymphocytic Leukemia
January 2019 Issue
 
 
 

Nearly every major medical breakthrough over the past 50 years can be attributed to new discoveries that were made possible through meticulous biomedical research. Many diseases and conditions that previously took a heavy toll on patients in terms of both morbidity and mortality are now either treatable or preventable thanks in large part to painstaking research that expanded the frontiers of scientific knowledge and moved the most promising basic research developments into tangible health benefits through human clinical trails. Ongoing research is also the key that will open the door to additional major medical advances and breakthroughs in the future.

Our staff at Medifocus is committed to keeping our subscribers to the Medifocus Digest Alert on Chronic Lymphocytic Leukemia abreast of the latest new research developments that have recently been published in the medical literature for this condition. In this issue of the Digest Alert, you will find a focused list of hand-picked journal article references that represent the latest advances in basic and clinical research for Chronic Lymphocytic Leukemia. These articles represent the current state-of-the-art of the research that will hopefully lead to additional major advances and breakthroughs in the clinical management of Chronic Lymphocytic Leukemia. You can access the summaries of each article referenced below by simply clicking on the article Title.

We will continue to update you with the latest scientific and clinical developments through the Medifocus Digest Alert on Chronic Lymphocytic Leukemia every 3 months. Thank you for your ongoing subscription to this publication.

Elliot Jacob, Ph.D.
Vice-President - Content
Medifocus.com, Inc.



1:Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation.
Authors:Buccheri V, Barreto WG, Fogliatto LM, Capra M, Marchiani M, Rocha V
Institution:Hospital das Clinicas da Faculdade de Medicina, Universidade de Sao Paulo/ICESP, Av. Dr. Eneas de Carvalho Aguiar, 155, 1 andar, Cerqueira Cesar, Sao Paulo, 05403-000, Brazil. vbbuccheri@gmail.com. Universidade Federal de Ciencias da Saude de Porto Alegre, Porto Alegre, Brazil. Paulo, Brazil.
Journal:Ann Hematol. 2018 Dec;97(12):2269-2278. doi: 10.1007/s00277-018-3503-6. Epub 2018 Oct 12.

2:Approaches to Chronic Lymphocytic Leukemia Therapy in the Era of New Agents: The Conundrum of Many Options.
Authors:Jain N, Thompson P, Ferrajoli A, Nabhan C, Mato AR, O'Brien S
Institution:From the Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX; Cardinal Health Specialty Solutions, Chicago, IL; Chronic Lymphocytic Leukemia Program, Memorial Sloan Kettering Cancer Center, New York, NY; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, CA.
Journal:Am Soc Clin Oncol Educ Book. 2018 May 23;(38):580-591. doi: 10.1200/EDBK_200691.

3:On the front line: first choice pharmacotherapeutics for chronic lymphocytic leukemia.
Authors:Samples LS, Graf SA
Institution:a Department of Medicine , University of Washington School of Medicine , Seattle , WA , USA. , WA , USA. WA , USA. Care System , Seattle , WA , USA.
Journal:Expert Opin Pharmacother. 2018 Oct;19(15):1675-1684. doi: 10.1080/14656566.2018.1524874. Epub 2018 Sep 27.

4:Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib.
Authors:Krause G, Hassenruck F, Hallek M
Institution:Department I of Internal Medicine, University of Cologne, Center of Integrated Oncology Koln Bonn, Cologne Cluster of Excellence on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany, guenter.krause@uk-koeln.de.
Journal:Drug Des Devel Ther. 2018 Aug 21;12:2577-2590. doi: 10.2147/DDDT.S142406. eCollection 2018.

5:Remission maintenance treatment options in chronic lymphocytic leukemia.
Authors:Egle A, Pleyer L, Melchardt T, Hartmann TN, Greil R
Institution:Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria. Electronic address: r.greil@salk.at.
Journal:Cancer Treat Rev. 2018 Nov;70:56-66. doi: 10.1016/j.ctrv.2018.08.003. Epub 2018 Aug 10.

6:Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty.
Authors:Hilal T, Betcher JA, Leis JF
Institution:Division of Hematology and Medical Oncology, Mayo Clinic, 5881 E. Mayo Blvd, Phoenix, AZ, 85054, USA. Phoenix, AZ, 85054, USA. leis.jose@mayo.edu.
Journal:Curr Hematol Malig Rep. 2018 Aug;13(4):237-243. doi: 10.1007/s11899-018-0461-y.

7:Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials.
Authors:Joffe E, Goldschmidt N, Bairey O, Fineman R, Ruchlemer R, Rahimi-Levene N, Shvidel L, Greenbaum U, Aviv A, Tadmor T, Braester A, Arad A, Polliack A, Herishanu Y
Institution:Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Journal:Eur J Haematol. 2018 Sep;101(3):399-406. doi: 10.1111/ejh.13129. Epub 2018 Aug 3.

8:Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II study.
Authors:Egle A, Steurer M, Melchardt T, Weiss L, Gassner FJ, Zaborsky N, Geisberger R, Catakovic K, Hartmann TN, Pleyer L, Voskova D, Thaler J, Lang A, Girschikofsky M, Petzer A, Greil R
Institution:Department of Internal Medicine III with Hematology and Medical Oncology, Oncologic Center, Paracelsus Medical University Salzburg, Mullner-Hauptstr. 48, 5020, Salzburg, Austria. r.greil@salk.at.; Salzburg Cancer Research Institute - Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and Cancer Cluster Salzburg (CCS), Salzburg, Austria. r.greil@salk.at.; Division of Hematology and Oncology, Laboratory for Molecular Genetics and Diagnostics, Innsbruck Medical University, Innsbruck, Austria.; Centre for Hematology and Medical Oncology, Kepler University Hospital, Linz, Austria.; Department for Internal Medicine IV, Hospital Wels-Grieskirchen, Wels, Austria.
Journal:Ann Hematol. 2018 Oct;97(10):1825-1839. doi: 10.1007/s00277-018-3380-z. Epub 2018 Jun 4.

9:Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia.
Authors:Cai Y, Feng L, Wang X
Institution:Department of Hematology, Provincial Hospital Affiliated to Shandong University, No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China. No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China. Electronic address: fenglili1982624@163.com. No. 324, Jingwu Road, Jinan, Shandong 250021, People's Republic of China; Shandong University School of Medicine, Jinan, Shandong 250012, People's Republic of China. Electronic address: xinw@sdu.edu.cn.
Journal:Crit Rev Oncol Hematol. 2018 Jun;126:24-31. doi: 10.1016/j.critrevonc.2018.03.022. Epub 2018 Mar 29.

10:Update on signal inhibitors in chronic lymphocytic leukemia.
Authors:Boddu P, Jain N
Institution:The University of Texas MD Anderson Cancer Center, Houston, Texas.
Journal:Clin Adv Hematol Oncol. 2018 Apr;16(4):279-288.

11:Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - Prelimary results.
Authors:Wasik-Szczepanek E, Szymczyk A, Kowal M, Nogalski A, Hus M
Institution:Department of Haematooncology and Bone Marrow Transplantation, Medical University. University. agnieszka.szymczyk.med@wp.pl. University. Lublin, Poland. University.
Journal:Ann Agric Environ Med. 2018 Mar 14;25(1):56-59. doi: 10.5604/12321966.1233571. Epub 2017 Feb 11.

12:Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Authors:Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, Owen C, Gerecitano J, Robak T, De la Serna J, Jaeger U, Cartron G, Montillo M, Humerickhouse R, Punnoose EA, Li Y, Boyer M, Humphrey K, Mobasher M, Kater AP
Institution:From the Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC (J.F.S.), and the John Curtin School of Medical Research, Australian National University, Canberra, ACT (J.D.) - all in Australia; the University of California School of Medicine, San Diego (T.J.K.), and Genentech, South San Francisco (E.A.P., Y.L., M. Mobasher) - both in California; University Hospital Cologne and the Center for Integrated Oncology Cologne-Bonn, Cologne, Germany (B.E.); St. James's University Hospital, Leeds (P.H.), and F. Hoffmann-La Roche, Welwyn Garden City (M.B., K.H.) - both in the United Kingdom; Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal (S.A.), and the Departments of Medicine and Oncology, University of Calgary, Calgary, AB (C.O.) - all in Canada; Memorial Sloan Kettering Cancer Center, New York (J.G.); the Department of Hematology, Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland (T.R.); Hospital Universitario 12 de Octubre, Madrid (J.D.S.); Medical University of Vienna, Department of Medicine I, Division of Hematology and Hemostaseology, Vienna (U.J.); the Department of Hematology, Centre Hospitalier Universitaire Montpellier, Montpellier, France (G.C.); the Department of Onco-Hematology, Division of Hematology, Niguarda Cancer Center, Niguarda Hospital, Milan (M. Montillo); AbbVie, North Chicago, IL (R.H.); and the Department of Hematology, Cancer Center Amsterdam, Academic Medical Center, Amsterdam (A.P.K.).
Journal:N Engl J Med. 2018 Mar 22;378(12):1107-1120. doi: 10.1056/NEJMoa1713976.

13:Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Authors:Brown JR, Hamadani M, Hayslip J, Janssens A, Wagner-Johnston N, Ottmann O, Arnason J, Tilly H, Millenson M, Offner F, Gabrail NY, Ganguly S, Ailawadhi S, Kasar S, Kater AP, Doorduijn JK, Gao L, Lager JJ, Wu B, Egile C, Kersten MJ
Institution:Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: Jennifer_brown@dfci.harvard.edu. of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA. USA. Cardiff University, Cardiff, UK. Boston, MA, USA. University, Rouen, France. USA. City, KS, USA. Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands. Lymphoma and Myeloma Center Amsterdam, Amsterdam, Netherlands.
Journal:Lancet Haematol. 2018 Apr;5(4):e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14.

14:Frontline Therapy of CLL: Evolving Treatment Paradigm.
Authors:Boddy CS, Ma S
Institution:Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 303 E Superior Street, Lurie 3-103, Chicago, IL, 60611, USA. Northwestern University Feinberg School of Medicine, 676 N St. Clair Street, Suite 850, Chicago, IL, 60611, USA. shuo-ma@northwestern.edu.
Journal:Curr Hematol Malig Rep. 2018 Apr;13(2):69-77. doi: 10.1007/s11899-018-0438-x.

15:Venetoclax: A new wave in hematooncology.
Authors:Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R
Institution:Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.; Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic; Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic; Faculty of Science, University of Ostrava, Ostrava, Czech Republic. Electronic address: tomas.jelinek@fno.cz.
Journal:Exp Hematol. 2018 May;61:10-25. doi: 10.1016/j.exphem.2018.02.002. Epub 2018 Mar 2.

16:Chronic lymphocytic leukaemia.
Authors:Hallek M, Shanafelt TD, Eichhorst B
Institution:Department of Internal Medicine, Center of Integrated Oncology Koln Bonn, University Hospital of Cologne, Cologne, Germany. Electronic address: michael.hallek@uni-koeln.de. University Hospital of Cologne, Cologne, Germany.
Journal:Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21.

17:Prognostic Factors in the Era of Targeted Therapies in CLL.
Authors:Boddu P, Ferrajoli A
Institution:Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX, 77030, USA. aferrajo@mdanderson.org.
Journal:Curr Hematol Malig Rep. 2018 Apr;13(2):78-90. doi: 10.1007/s11899-018-0439-9.

18:Rituximab, cladribine, and cyclophosphamide (RCC) induction with rituximab maintenance in chronic lymphocytic leukemia: PALG - CLL4 (ML21283) trial.
Authors:Robak T, Blonski J, Skotnicki AB, Piotrowska M, Wrobel T, Rybka J, Kloczko J, Bolkun L, Budziszewska BK, Walczak U, Uss A, Fidecka M, Smolewski P
Institution:Department of Hematology, Copernicus Memorial Hospital, Medical University of Lodz, Lodz, Poland. Lodz, Lodz, Poland. Wroclaw Medical University, Wroclaw, Poland. Wroclaw Medical University, Wroclaw, Poland. Warsaw, Poland. Warsaw, Poland. University of Lodz, Lodz, Poland.
Journal:Eur J Haematol. 2018 May;100(5):465-474. doi: 10.1111/ejh.13042. Epub 2018 Mar 22.

19:Subcutaneous rituximab with recombinant human hyaluronidase in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Authors:Hill SL, Davies A
Institution:Medical Oncology, Southampton General Hospital, Southampton, UK. Southampton, UK.
Journal:Future Oncol. 2018 Jul;14(17):1691-1699. doi: 10.2217/fon-2017-0574. Epub 2018 Feb 6.

20:Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice.
Authors:Reiser M, Dorfel S, Hensel M, Hoesl M, Jordan WO, Koenigsmann M, Meyer D, Reichert D, Schwarzer A, Marquardt M, Kellershohn K, Jentsch-Ullrich K
Institution:Praxis internistischer und onkologischer Hamatologie (PIOH), Cologne, Germany.
Journal:Eur J Haematol. 2018 May;100(5):455-464. doi: 10.1111/ejh.13040. Epub 2018 Mar 22.

21:Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study.
Authors:Dartigeas C, Van Den Neste E, Leger J, Maisonneuve H, Berthou C, Dilhuydy MS, De Guibert S, Lepretre S, Bene MC, Nguyen-Khac F, Letestu R, Cymbalista F, Rodon P, Aurran-Schleinitz T, Vilque JP, Tournilhac O, Mahe B, Laribi K, Michallet AS, Delmer A, Feugier P, Levy V, Delepine R, Colombat P, Leblond V
Institution:Hematologie et Therapie Cellulaire, Hopital Bretonneau, CHU Tours, Tours, France. Electronic address: c.dartigeas@chu-tours.fr. Belgium. Roche Sur Yon, France. Pessac, France. Normandie, Rouen, France. U1138, Universite Paris 6, Paris, France. Clermont-Ferrand, Clermont-Ferrand, France. Berard, Lyon, France. Champagne-Ardenne, Reims, France. Vandoeuvre-les-Nancy, France. Universite Paris 13, Bobigny, France. Tours, France.
Journal:Lancet Haematol. 2018 Feb;5(2):e82-e94. doi: 10.1016/S2352-3026(17)30235-1. Epub 2017 Dec 20.

22:Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Authors:Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC
Institution:The Ohio State University, Columbus, OH, USA. Philadelphia, PA, USA. USA. Pharmacy, Ain Shams University, Cairo, Egypt. USA. address: john.byrd@osumc.edu.
Journal:Lancet Oncol. 2018 Jan;19(1):65-75. doi: 10.1016/S1470-2045(17)30909-9. Epub 2017 Dec 12.

23:Ibrutinib and its use in the treatment of chronic lymphocytic leukemia.
Authors:Frustaci AM, Tedeschi A, Deodato M, Mazzucchelli M, Cairoli R, Montillo M
Institution:Dept of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano, Piazza Ospedale Maggiore 3, Milano, Italy.
Journal:Future Oncol. 2018 Apr;14(8):681-697. doi: 10.2217/fon-2017-0466. Epub 2017 Dec 15.

24:Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review/meta-analysis.
Authors:Kharfan-Dabaja MA, Moukalled N, Reljic T, El-Asmar J, Kumar A
Institution:Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, USA; Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, FL, USA. University of Beirut Medical Center, Beirut, Lebanon. Morsani College of Medicine, Tampa, FL, USA. Morsani College of Medicine, Tampa, FL, USA. Electronic address: Akumar1@health.USF.edu.
Journal:Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):53-64. doi: 10.1016/j.hemonc.2017.11.001. Epub 2017 Nov 26.

25:Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Authors:Thompson PA, Burger JA
Institution:a Department of Leukemia , The University of Texas MD Anderson Cancer Center , Houston , TX , USA. Houston , TX , USA.
Journal:Expert Opin Investig Drugs. 2018 Jan;27(1):31-42. doi: 10.1080/13543784.2018.1404027. Epub 2017 Nov 15.

26:Advances in chronic lymphocytic leukemia pharmacotherapy.
Authors:Gomes LC, Ferrao ALM, Evangelista FCG, de Almeida TD, Barbosa RC, Carvalho MDG, de Paula Sabino A
Institution:Departamento de Analises Clinicas e Toxicologicas, Faculdade de Farmacia, Universidade Federal de Minas Gerais, Address: 6627, Presidente Antonio Carlos Ave, Pampulha, Zip Code 31270-901, Belo Horizonte, MG, Brazil. Electronic address: adriansabin01@gmail.com.; Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Address: 6627, Presidente Antonio Carlos Ave, Pampulha, Zip Code 31270-901, Belo Horizonte, MG, Brazil.
Journal:Biomed Pharmacother. 2018 Jan;97:349-358. doi: 10.1016/j.biopha.2017.10.105. Epub 2017 Nov 6.

27:Approach to Richter transformation of chronic lymphocytic leukemia in the era of novel therapies.
Authors:Khan M, Siddiqi R, Thompson PA
Institution:Department of Leukemia, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Houston, TX, 77030-4009, USA. Holcombe Blvd, Houston, TX, 77030-4009, USA. pathompson2@mdanderson.org.
Journal:Ann Hematol. 2018 Jan;97(1):1-15. doi: 10.1007/s00277-017-3149-9. Epub 2017 Oct 23.

28:Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
Authors:Lee LJ, Toze CL, Huang SJT, Gillan TL, Connors JM, Sehn LH, Bruyere H, Leitch H, Ramadan KM, Gerrie AS
Institution:a Department of Medicine, Division of Hematology , University of British Columbia , Vancouver , Canada. University of British Columbia , Vancouver , Canada. University of British Columbia , Vancouver , Canada. , St. John's , Canada. Vancouver , Canada. Vancouver , Canada. University of British Columbia , Vancouver , Canada. Vancouver , Canada. Vancouver , Canada. University of British Columbia , Vancouver , Canada. Vancouver , Canada.
Journal:Leuk Lymphoma. 2018 Jun;59(6):1356-1363. doi: 10.1080/10428194.2017.1387904. Epub 2017 Oct 16.

29:The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
Authors:Mescher C, Gilbertson D, Randall NM, Tarchand G, Tomaska J, Baumann Kreuziger L, Morrison VA
Institution:a Division of Hematology, Oncology and Transplant , University of Minnesota , Minneapolis , MN , USA. Minneapolis , MN , USA. Minneapolis , MN , USA. Minneapolis , MN , USA.
Journal:Leuk Lymphoma. 2018 Jun;59(6):1348-1355. doi: 10.1080/10428194.2017.1375109. Epub 2017 Sep 14.

30:Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Authors:Olin JL, Griffiths CL, Smith MB
Institution:1 Levine College of Health Sciences, Wingate University School of Pharmacy, Wingate, NC, USA. Wingate, NC, USA. USA.
Journal:J Oncol Pharm Pract. 2018 Oct;24(7):517-524. doi: 10.1177/1078155217718383. Epub 2017 Jul 11.

31:Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
Authors:Wendtner CM, Gregor M
Institution:a Klinikum Schwabing, Department of Internal Medicine I , Academic Teaching Hospital of University of Munich , Munich , Germany.
Journal:Leuk Lymphoma. 2018 Feb;59(2):300-310. doi: 10.1080/10428194.2017.1330474. Epub 2017 Jun 1.

32:Treatment of Del17p and/or aberrant TP53 chronic lymphocytic leukemia in the era of novel therapies.
Authors:Rafei H, Kharfan-Dabaja MA
Institution:Department of Internal Medicine, George Washington University School of Medicine, Washington, DC, USA. Research Institute, Tampa, FL, USA; Department of Oncologic Sciences, College of Medicine, University of South Florida Morsani, Tampa, FL, USA. Electronic address: Mohamed.Kharfan-Dabaja@Moffitt.org.
Journal:Hematol Oncol Stem Cell Ther. 2018 Mar;11(1):1-12. doi: 10.1016/j.hemonc.2017.04.002. Epub 2017 May 19.

For a FREE PREVIEW of the Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To purchase a copy of the COMPLETE Medifocus Guidebook on Chronic Lymphocytic Leukemia click here

To subscribe to additional FREE Medifocus Digest Alert on other disease/condition areas click here

  
Get the Medifocus Guidebook on Chronic Lymphocytic Leukemia...
at a Special 20% Discount


Medifocus Guidebook on Chronic Lymphocytic Leukemia

Updated: January 2, 2019
201 Pages

This one of a kind Guidebook offers:

  • Answers to your critical health questions including the latest treatments, clinical trials, and expert research.
     
  • High Quality, Professional level information you can trust and understand culled from the latest peer-reviewed journals.
     
  • Timely, up to date content with free guidebook updates for 1 year.
     
  • A unique resource to find leading experts, institutions, and support organizations including contact information and hyperlinks.
     
  • Over 130,000 Guidebooks Sold
     
  • 100% Risk Free Money Back Guarantee



ORDER THE GUIDEBOOK

The Medifocus Guidebook on Chronic Lymphocytic Leukemia is available in the following two convenient formats:

PRINTED GUIDEBOOK

Soft-cover book that is available for immediate shipping via either U.S. Priority Mail or International AirMail (outside the U.S.).

  • Regular List Price = $36.95
  • Less 20% Discount = - $7.40
  • Discounted Price = $29.55(excluding shipping & handling)

Order the Printed Guidebook

DIGITAL GUIDEBOOK

Available for immediate download as a PDF document.

  • Regular List Price = $27.95
  • Less 20% Discount = - $5.60
  • Discounted Price = $22.35

Order the Digital Guidebook



Order by Phone

Call Toll Free in the U.S.
1-800-965-3002

From Outside the U.S.
1-301-649-9300

You can also receive a 20% discount when you order your Guidebook by phone.

To receive your 20% discount, simply mention the Discount Coupon Code below to the customer service representative taking your order.

Discount Coupon Code for
Phone Orders

CL13341522

Coupon Expires: March 18, 2019



What Our Customers Are Saying...

"I was recently diagnosed with CLL and searched all over the Web for information. I found the MediFocus Guidebook on Chronic Lymphocytic Leukemia to be a very useful resource. The information about chemotherapy was most important to me as well as recent studies concerning general treatments for this condition. The most valuable information was contained in the extensive references listed which were easy to access with a simple 'mouse' click. You are welcome to use my name as a reference."
G.C.
Coedpoeth, United Kingdom



  
Medifocus Digest Alert is published by Medifocus, Inc.
6810 Park Heights Avenue, Suite C5, Baltimore, MD 21215 USA
Copyright © 2019 Medifocus, Inc. All rights reserved.